Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
NCT ID: NCT06360419
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
346 participants
INTERVENTIONAL
2024-03-18
2025-03-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Pramipexole for Treatment-Resistant Depression
NCT00231959
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder
NCT01733654
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
NCT04937829
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
NCT01098240
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Solriamfetol 300 mg
Up to 6 weeks
Solriamfetol 300 mg
Solriamfetol tablets, taken once daily
Placebo
Up to 6 weeks
Placebo
Placebo tablets, taken once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solriamfetol 300 mg
Solriamfetol tablets, taken once daily
Placebo
Placebo tablets, taken once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current major depressive episode
* Male or female, aged 18 to 65 inclusive
Exclusion Criteria
* Unable to comply with study procedures
* Medically inappropriate for study participation in the opinion of the investigator
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axsome Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Site
Little Rock, Arkansas, United States
Clinical Research Site
Bellflower, California, United States
Clinical Research Site
Encino, California, United States
Clinical Research Site
Lemon Grove, California, United States
Clinical Research Site
Los Angeles, California, United States
Clinical Research Site
Montclair, California, United States
Clinical Research Site
Oceanside, California, United States
Clinical Research Site
Redlands, California, United States
Clinical Research Site
Riverside, California, United States
Clinical Research Site
Sherman Oaks, California, United States
Clinical Research Site
Torrance, California, United States
Clinical Research Site
Upland, California, United States
Clinical Research Site
Walnut Creek, California, United States
Clinical Research Site
Cromwell, Connecticut, United States
Clinical Research Site
Brandon, Florida, United States
Clinical Research Site
Hialeah, Florida, United States
Clinical Research Site
Jacksonville, Florida, United States
Clinical Research Site
Orlando, Florida, United States
Clinical Research Site
Orlando, Florida, United States
Clinical Research Site
Orlando, Florida, United States
Clinical Research Site
Chicago, Illinois, United States
Clinical Research Site
Overland Park, Kansas, United States
Clinical Research Site
New Orleans, Louisiana, United States
Clinical Research Site
Boston, Massachusetts, United States
Clinical Research Site
Saint Charles, Missouri, United States
Clinical Research Site
Las Vegas, Nevada, United States
Clinical Research Site
Brooklyn, New York, United States
Clinical Research Site
Rochester, New York, United States
Clinical Research Site
Staten Island, New York, United States
Clinical Research Site
Hickory, North Carolina, United States
Clinical Research Site
Cincinnati, Ohio, United States
Clinical Research Site
Oklahoma City, Oklahoma, United States
Clinical Research Site
Media, Pennsylvania, United States
Clinical Research Site
Philadelphia, Pennsylvania, United States
Clinical Research Site
Memphis, Tennessee, United States
Clinical Research Site
Austin, Texas, United States
Clinical Research Site
Dallas, Texas, United States
Clinical Research Site
Friendswood, Texas, United States
Clinical Research Site
Wichita Falls, Texas, United States
Clinical Research Site
Everett, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Axsome Therapeutics Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SOL-MDD-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.